Markets & Stocks

Stock quotes, market indicators and the latest market news.

Market Summary Market News Stock Quotes Market Movers
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

7.055 -0.235 (-3.22%)
Delayed Quote Updated: 1:48 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
3 Reasons to Avoid OCUL and 1 Stock to Buy Instead
Over the last six months, Ocular Therapeutix’s shares have sunk to $7.74, producing a disappointing 7.1% loss - a stark contrast to the S&P 500’s 16.6% gain.... 
Via StockStory
Topics Stocks
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid S... 
Via StockStory
News headline image
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success ↗
Ocular Therapeutix (NASDAQ:OCUL) said it remains on track to submit a U.S. marketing application for AXPAXLI in the fourth quarter of this year, following what Chief Executive Officer Pravin Dugel... 
Via MarketBeat
Ocular Therapeutix Inc (NASDAQ:OCUL) Misses on Revenue and EPS in Q1 2026, Stock Dips ↗
Via Chartmill
News headline image
1 Cash-Heavy Stock on Our Buy List and 2 Facing Challenges
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c... 
Via StockStory
News headline image
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Oc... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Ocular Therapeutix (NASDAQ:OCUL) Beats Expectations in Strong Q2 CY2026
Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) reported Q2 CY2026 results beating Wall Street’s revenue expectations, but sales wer... 
Via StockStory
News headline image
3 Healthcare Stocks with Questionable Fundamentals
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on... 
Via StockStory
News headline image
3 Russell 2000 Stocks That Concern Us
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,... 
Via StockStory
News headline image
Pharmaceuticals Stocks Q1 In Review: Ocular Therapeutix (NASDAQ:OCUL) Vs Peers
Let’s dig into the relative performance of Ocular Therapeutix (NASDAQ:OCUL) and its peers as we unravel the now-completed Q1 pharmaceuticals earnings season.... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment ↗
Ocular Therapeutix (NASDAQ:OCUL) said it remains on track to submit a New Drug Application for AXPAXLI in wet age-related macular degeneration in the fourth quarter, after what Executive Chairman,... 
Via MarketBeat
News headline image
3 Cash-Burning Stocks with Open Questions
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sh... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Small-Cap Stocks with Open Questions
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and... 
Via StockStory
News headline image
Ocular Therapeutix (OCUL): Buy, Sell, or Hold Post Q1 Earnings?
Over the past six months, Ocular Therapeutix’s shares (currently trading at $10.37) have posted a disappointing 18.5% loss, well below the S&P 500’s 7.8% gai... 
Via StockStory
Topics Stocks
News headline image
Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos
Check out the companies making headlines yesterday: Nubank (NYSE:NU): Digital banking platform Nubank (NYSE:NU) rose by 3.2% on Wednesday after the company r... 
Via StockStory
Topics Economy
News headline image
Why Ocular Therapeutix (OCUL) Stock Is Up Today
What Happened? Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) jumped 7.2% in the afternoon session after the company anno... 
Via StockStory
News headline image
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? ↗
Two biotech innovators, two very different risk profiles: one with commercial products and another betting on next-gen gene editing breakthroughs. 
Via The Motley Fool
News headline image
3 of Wall Street’s Favorite Stocks That Concern Us
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
1 Russell 2000 Stock to Research Further and 2 Facing Headwinds
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,... 
Via StockStory
News headline image
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗
Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases. 
Via The Motley Fool
Topics Regulatory Compliance Stocks
News headline image
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why Ocular Therapeutix (OCUL) Stock Is Nosediving
What Happened? Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell 5.8% in the afternoon session after the company report... 
Via StockStory
News headline image
Ocular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings
Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) missed Wall Street’s revenue expectations in Q1 CY2026, with sales flat year on year... 
Via StockStory
News headline image
Ocular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To Expect
Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) will be announcing earnings results this Tuesday before the bell. Here’s what to loo... 
Via StockStory
News headline image
1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have ou... 
Via StockStory
News headline image
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health. 
Via The Motley Fool
News headline image
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
1 Cash-Heavy Stock to Research Further and 2 We Brush Off
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg... 
Via StockStory
News headline image
3 Reasons to Avoid OCUL and 1 Stock to Buy Instead
Shareholders of Ocular Therapeutix would probably like to forget the past six months even happened. The stock dropped 29.1% and now trades at $8.62. This was... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.